PSA Test: Prostate-Specific Antigen Screening Guide

The prostate-specific antigen (PSA) test is one of the most widely used and simultaneously most debated cancer screening tools in modern medicine. Measuring PSA in blood offers a non-invasive window into prostate health — but interpreting the result requires understanding that PSA is prostate-specific, not cancer-specific. Elevated PSA can reflect cancer, benign enlargement, infection, inflammation, or even routine physical activity. This guide explains what PSA measures, what the numbers mean, and how to make informed decisions about screening and follow-up.

Table of Contents

1. Overview
2. When Ordered — Age-Based Screening
3. Reference Ranges
4. PSA Velocity and PSA Density
5. Screening Controversy
6. What Elevated PSA Means
7. Next Steps After Elevated PSA
8. References

Overview

Prostate-specific antigen is a serine protease enzyme (kallikrein-3) produced almost exclusively by the epithelial cells of the prostate gland. Its physiological role is to liquefy the seminal coagulum after ejaculation, improving sperm motility. Normally, only tiny amounts leak into the bloodstream. When the prostate gland is disrupted — by cancer, infection, inflammation, or mechanical disruption of the glandular architecture — more PSA enters the circulation, raising serum levels.

PSA circulates in two forms:

• Bound PSA: Complexed with serum proteins (primarily alpha-1-antichymotrypsin); comprises 70–90% of total PSA
• Free PSA: Unbound, circulating freely; comprises 10–30% of total PSA

The ratio of free to total PSA (the free PSA ratio or %fPSA) provides additional discrimination between benign and malignant causes of PSA elevation. Cancer cells tend to produce more bound PSA relative to free PSA, so a lower free PSA percentage suggests a higher probability of cancer.

PSA was approved by the FDA for prostate cancer monitoring in 1986 and for screening in combination with digital rectal examination in 1994. It revolutionized the detection of prostate cancer at earlier, more treatable stages — but also opened a prolonged debate about overdiagnosis and overtreatment of clinically insignificant cancers.

When Ordered — Age-Based Screening

PSA testing recommendations vary by organization and individual risk profile. The following represents current consensus from major professional societies:

Average Risk Men

• Age 40–54: Routine screening not generally recommended for average-risk men. Consider baseline PSA to establish personal trajectory.
• Age 55–69: Individualized decision after informed discussion of benefits and harms with physician. This is the age range with the most robust evidence for PSA screening benefit.
• Age 70 and older: Routine screening generally not recommended; benefits are unlikely to outweigh harms in most men. Exception for healthy men with long life expectancy and high personal preference for screening.

High Risk Men — Earlier Screening (Starting at Age 40–45)

• African American men: Face a 1.6 times higher incidence and 2.4 times higher mortality from prostate cancer compared to white men; generally recommended to begin screening at age 40–45
• First-degree relative diagnosed with prostate cancer before age 65: Family history roughly doubles lifetime risk
• BRCA2 mutation carriers: Associated with significantly higher risk of aggressive prostate cancer; screening from age 40 recommended
• Lynch syndrome: Moderately elevated prostate cancer risk; early screening appropriate

Clinical Indications (Any Age)

• Lower urinary tract symptoms (difficulty urinating, weak stream, nocturia) suggesting BPH or prostatitis
• Abnormal digital rectal examination (DRE) findings
• Monitoring during and after treatment for known prostate cancer
• Elevated PSA on prior testing requiring follow-up

Reference Ranges

Total PSA (ng/mL)

The traditional cutoff of 4.0 ng/mL was established in early PSA studies and has been the most widely used threshold. However, prostate cancer can be present at any PSA level. The Prostate Cancer Prevention Trial found prostate cancer (including some high-grade cancers) in 15% of men with PSA below 4.0 ng/mL and normal DRE. More contemporary guidance uses PSA in context rather than applying a single fixed cutoff.

Age-adjusted PSA reference ranges have been proposed to account for the fact that PSA rises with age due to benign prostate enlargement:

• Ages 40–49: <2.5 ng/mL
• Ages 50–59: <3.5 ng/mL
• Ages 60–69: <4.5 ng/mL
• Ages 70–79: <6.5 ng/mL

Free PSA Ratio (free PSA / total PSA × 100%)

The free PSA ratio is most useful in the gray zone (total PSA 4–10 ng/mL). A free PSA ratio below 10% is associated with a 50–65% risk of prostate cancer on biopsy; a ratio above 25% is associated with only 8–15% cancer risk. The ratio should be interpreted together with total PSA, DRE findings, and clinical context.

PSA Velocity and PSA Density

PSA Velocity (PSAV)

PSA velocity measures the rate of PSA change over time. Because cancer tends to cause PSA to rise faster than benign conditions, velocity adds prognostic value beyond a single PSA measurement. Concerning thresholds include:

• PSAV greater than 0.75 ng/mL per year in men with PSA above 4.0 ng/mL
• PSAV greater than 0.4 ng/mL per year in men with PSA below 4.0 ng/mL

PSA velocity calculations require at least two to three measurements over at least 12–18 months, obtained using the same laboratory assay. Short-interval measurements are unreliable due to biological variation in PSA.

PSA Doubling Time (PSADT)

PSA doubling time quantifies how rapidly PSA is increasing on a logarithmic scale. Very short doubling times (less than 3 months) after prostate cancer treatment suggest aggressive recurrent disease. In the post-treatment setting, PSADT is one of the strongest predictors of metastasis and cancer-specific mortality.

PSA Density (PSAD)

PSA density normalizes total PSA to prostate volume as measured by transrectal ultrasound or MRI. A larger prostate produces more PSA from benign tissue. The formula is: PSAD = total PSA (ng/mL) ÷ prostate volume (mL).

• PSAD below 0.10: Generally reassuring; benign enlargement is more likely
• PSAD above 0.15: Increased concern for cancer; biopsy consideration increases

PSA density is particularly useful in distinguishing cancer from BPH in men with large prostates and moderately elevated PSA.

Screening Controversy

The PSA screening debate is one of the most nuanced in preventive medicine. Two landmark randomized controlled trials — the European Randomized Study of Screening for Prostate Cancer (ERSPC) and the U.S. Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial — reached different conclusions about PSA screening benefit.

Arguments Supporting PSA Screening

• The ERSPC trial demonstrated a 21% reduction in prostate cancer mortality with PSA screening in men aged 55–69 after 13 years of follow-up
• PSA-detected cancers are more often organ-confined and amenable to curative treatment
• Metastatic prostate cancer rates declined substantially following PSA screening adoption in the 1990s
• Long-term ERSPC data (16-year follow-up) showed even greater mortality benefit

Arguments Against Routine PSA Screening

• Overdiagnosis: An estimated 20–50% of PSA-detected prostate cancers are indolent tumors that would never have caused symptoms or death during the man's lifetime
• Overtreatment: Many detected cancers are subjected to radical prostatectomy or radiation, causing incontinence, erectile dysfunction, and other significant harms
• False positives: PSA elevation leads to anxiety, additional testing, and prostate biopsies, which carry risks of bleeding and infection
• The PLCO trial found no mortality benefit from screening, though contamination (screening in the control arm) limits interpretation

Current USPSTF Recommendation (2018)

The U.S. Preventive Services Task Force gives PSA screening for men aged 55–69 a Grade C recommendation — meaning the service offers a small net benefit, and clinicians should offer it to selected patients based on individual circumstances and preferences. For men 70 and older, the USPSTF recommends against routine PSA screening (Grade D).

The American Urological Association (AUA) and American Cancer Society recommend shared decision-making with emphasis on individual values, life expectancy, and risk factors — particularly for men in the 55–69 age range where evidence of benefit is strongest.

What Elevated PSA Means

A key clinical point that patients must understand: PSA is prostate-specific, not cancer-specific. An elevated PSA result is not a diagnosis of cancer. Many common, benign conditions raise PSA:

Benign Causes of Elevated PSA

• Benign prostatic hyperplasia (BPH): The most common cause of elevated PSA in older men. As the prostate enlarges benignly, more PSA is produced. A prostate of 100 mL in a man with BPH may generate a PSA of 10–15 ng/mL with no cancer present.
• Prostatitis (bacterial or non-bacterial): Prostate infection or inflammation dramatically disrupts the glandular architecture, releasing PSA into the bloodstream. Acute bacterial prostatitis can raise PSA to 30–100+ ng/mL. PSA should be rechecked after antibiotic treatment.
• Urinary tract infection (UTI): Bacterial infection can extend to prostate tissue and transiently elevate PSA
• Recent ejaculation: PSA is present in semen and seminal fluid can contribute to transient elevation. Abstinence from ejaculation for 48 hours before PSA testing is recommended for accurate results.
• Digital rectal examination (DRE): May slightly raise PSA; the traditional recommendation to draw PSA before DRE is based on older data, and the clinical significance is small
• Prostate biopsy or procedure: PSA may be markedly elevated for weeks to months after biopsy, cystoscopy, or TURP
• Vigorous cycling or horseback riding: Perineal pressure may transiently raise PSA; recommend avoiding intense cycling for 48 hours before testing
• 5-alpha reductase inhibitors (finasteride, dutasteride): These drugs, used for BPH, reduce PSA by approximately 50%; a man on these medications with a PSA of 2.0 ng/mL has an effective PSA of approximately 4.0 ng/mL

Cancer-Related PSA Elevation

Prostate cancer is a significant but not the most common cause of PSA elevation in the 4–10 ng/mL gray zone. In this range, the probability of cancer on biopsy is approximately 25–30%. With PSA above 10 ng/mL, cancer probability on biopsy rises to 50–75%.

Next Steps After Elevated PSA

An elevated PSA prompts a systematic evaluation pathway rather than immediate biopsy. The evaluation may include several steps:

Step 1: Rule Out Transient Causes

• Treat prostatitis or UTI if present; recheck PSA in 6–8 weeks after antibiotic therapy
• Confirm recent ejaculation or vigorous activity did not cause a transient spike; recheck after appropriate abstinence
• Ensure medications (5-ARIs) are accounted for when interpreting results

Step 2: Repeat PSA Testing

If no transient cause is identified, repeat PSA in 6–8 weeks at the same laboratory. Single PSA measurements are subject to biological variation of 15–20%. Confirmed persistent elevation strengthens the case for further evaluation.

Step 3: Free PSA Ratio

If total PSA is in the gray zone (4–10 ng/mL), free PSA ratio can help stratify risk and potentially avoid biopsy in men with reassuring ratios above 25%.

Step 4: Advanced PSA Biomarkers

Several FDA-approved biomarker tests can further refine cancer risk assessment:

• 4Kscore: Combines total PSA, free PSA, intact PSA, and human kallikrein 2 with clinical variables to predict probability of high-grade (Gleason ≥7) cancer
• Prostate Health Index (phi): Incorporates [-2]proPSA, free PSA, and total PSA; outperforms total PSA and free PSA ratio for detecting clinically significant cancer
• PCA3 (urine test): Measures a prostate-specific non-coding RNA that is overexpressed in prostate cancer; performed on post-DRE urine sample
• SelectMDx (urine): Detects two prostate cancer biomarkers (HOXC6 and DLX1) in post-DRE urine

Step 5: Multiparametric MRI (mpMRI)

MRI of the prostate before biopsy has become standard of care at many centers. mpMRI is reported using the PI-RADS (Prostate Imaging Reporting and Data System) scoring system on a 1–5 scale. PI-RADS scores of 1–2 are unlikely to harbor clinically significant cancer; scores of 4–5 have a high probability. MRI-guided fusion biopsy of suspicious lesions improves detection of clinically significant cancers while reducing detection of insignificant ones.

Step 6: Prostate Biopsy

Transrectal or transperineal prostate biopsy (typically 12 cores) remains the definitive diagnostic procedure. Pathology reports the Gleason grade (now reported as Grade Groups 1–5), number of positive cores, and percentage of cancer involvement. Grade Group 1 (Gleason 6) cancers have very low metastatic potential and may be managed with active surveillance rather than immediate treatment.

Back to Table of Contents

References

1. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320–1328.
2. Andriole GL, Crawford ED, Grubb RL 3rd, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310–1319.
3. U.S. Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;319(18):1901–1913.
4. Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA Guideline. J Urol. 2013;190(2):419–426.
5. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med. 2004;350(22):2239–2246.
6. Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease. JAMA. 1998;279(19):1542–1547.
7. Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Eur Urol. 2017;71(4):618–629.
8. Ahmed HU, El-Shater Bosaily A, Brown LC, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389(10071):815–822.
9. Filella X, Fernández-Galan E, Fernández Bonifacio R, Foj L. Emerging biomarkers in the diagnosis of prostate cancer. Pharmgenomics Pers Med. 2018;11:83–94.
10. Bruinsma SM, Bangma CH, Carroll PR, et al. Active surveillance for prostate cancer: a narrative review of clinical guidelines. Nat Rev Urol. 2016;13(3):151–167.
11. Loeb S, Vellekoop A, Ahmed HU, et al. Systematic review of complications of prostate biopsy. Eur Urol. 2013;64(6):876–892.
12. Welch HG, Albertsen PC. Reconsidering prostate cancer mortality — the future of PSA screening. N Engl J Med. 2020;382(16):1557–1563.